Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Baharav

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Immunology, Immunotherapy : CII|June 1, 1996
Anti-tyrosinase antibodies in malignant melanomaO Merimsky, E Baharav, Y Shoenfeld, et al.
Clinical and Experimental Immunology|July 1, 1996
Tyrosinase as an autoantigen in patients with vitiligoE Baharav, O Merimski, Y Shoenfeld, et al.
American Journal of Clinical Oncology|December 1, 1996
Melanoma-associated hypopigmentation: where are the antibodies?O Merimsky, Y Shoenfeld, E Baharav, et al.
Clinical and Experimental Rheumatology|July 1, 1996
Superantigens and experimental SLE induced by idiotypic dysregulationE Baharav, H Gur, P Fishman, et al.
The Journal of Clinical Investigation|March 1, 1989
Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparinsO Lider, E Baharav, Y A Mekori, et al.
Melanoma Research|October 1, 1995
Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigenE Baharav, O Merimsky, M Altomonte, et al.
European Journal of Immunology|March 1, 1990
Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunityO Lider, Y A Mekori, T Miller, et al.
Biochemical and Biophysical Research Communications|March 2, 1999
A cellulose-binding domain-fused recombinant human T cell connective tissue-activating peptide-III manifests heparanase activityM Rechter, O Lider, L Cahalon, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Immunology, Immunotherapy : CII|June 1, 1996
Anti-tyrosinase antibodies in malignant melanomaO Merimsky, E Baharav, Y Shoenfeld, et al.
Clinical and Experimental Immunology|July 1, 1996
Tyrosinase as an autoantigen in patients with vitiligoE Baharav, O Merimski, Y Shoenfeld, et al.
American Journal of Clinical Oncology|December 1, 1996
Melanoma-associated hypopigmentation: where are the antibodies?O Merimsky, Y Shoenfeld, E Baharav, et al.
Clinical and Experimental Rheumatology|July 1, 1996
Superantigens and experimental SLE induced by idiotypic dysregulationE Baharav, H Gur, P Fishman, et al.
The Journal of Clinical Investigation|March 1, 1989
Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparinsO Lider, E Baharav, Y A Mekori, et al.
Melanoma Research|October 1, 1995
Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigenE Baharav, O Merimsky, M Altomonte, et al.
European Journal of Immunology|March 1, 1990
Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunityO Lider, Y A Mekori, T Miller, et al.
Biochemical and Biophysical Research Communications|March 2, 1999
A cellulose-binding domain-fused recombinant human T cell connective tissue-activating peptide-III manifests heparanase activityM Rechter, O Lider, L Cahalon, et al.
Pageof 2